Serina Therapeutics Inc (SER) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Serina Therapeutics Inc (SER) has a cash flow conversion efficiency ratio of -2.415x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.85 Million) by net assets ($1.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Serina Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Serina Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Serina Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Serina Therapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Serina Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Serina Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alphawave IP Group PLC
LSE:AWE
|
-0.107x |
|
Mhethanol Co. Ltd.
KO:023150
|
0.177x |
|
BMG Resources Ltd
AU:BMG
|
-0.022x |
|
InfoBank Corporation
KQ:039290
|
-0.003x |
|
Coats Group PLC
LSE:COA
|
0.184x |
|
Matichon Public Company Limited
BK:MATI
|
-0.002x |
|
Zenta Group Company Limited
NASDAQ:ZTG
|
N/A |
|
Nagarjuna Fertilizers and Chemicals Limited
NSE:NAGAFERT
|
0.074x |
Annual Cash Flow Conversion Efficiency for Serina Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Serina Therapeutics Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Serina Therapeutics Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $508.00K | $-17.14 Million | -33.734x | -44098.95% |
| 2023-12-31 | $-32.29 Million | $-2.48 Million | 0.077x | -36.04% |
| 2022-12-31 | $-17.32 Million | $-2.08 Million | 0.120x | -36.75% |
| 2021-12-31 | $-11.88 Million | $-2.25 Million | 0.190x | -86.92% |
| 2020-12-31 | $-5.40 Million | $-7.82 Million | 1.449x | +137.31% |
| 2019-12-31 | $2.62 Million | $-10.16 Million | -3.882x | -299.69% |
| 2018-12-31 | $8.23 Million | $-8.00 Million | -0.971x | -28.57% |
| 2017-12-31 | $8.32 Million | $-6.29 Million | -0.755x | -300.60% |
| 2016-12-31 | $-22.38 Million | $-8.43 Million | 0.377x | -- |
About Serina Therapeutics Inc
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more